School of Biomedical Sciences
生物醫學學院
The Chinese University of Hong Kong 香港中文大學

Prof RUDD John Anthony

John Rudd

Professor

B.Sc., Ph.D.

Telephone:  3943 6789

E-mail:  This email address is being protected from spambots. You need JavaScript enabled to view it.

Website:  http://jar-labs.vomifix.com

Address:

 704A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

Publons: https://publons.com/researcher/1859580/john-a-rudd/

ORCID: https://orcid.org/0000-0002-8316-0792

 

  

  

Biography

Prof. RUDD John Anthony (陸臻賢) worked with Glaxo Group Research in the late 1980s to explore the potential use of the 5-HT3 receptor antagonist, ondansetron, to antagonize chemotherapy- and drug-induced emesis.  He was also part of a team that mapped 5-HT3 receptor distribution in the human and ferret brainstem and first to show increases in of 5-HT in the plasma of patients receiving cisplatin-based chemotherapy.  Pioneered the use of the ferret to model chemotherapy-induced acute and delayed emesis (now a gold standard model) and discovered that NK1 tachykinin antagonists could be used to prevent the acute and delayed phases of emesis induced by cisplatin: now NK1 tachykinin antagonists are a cornerstone of treatment for delayed emesis.  Recently he collaborated with Helsinn on the development of the second generation 5-HT3 and NK1 receptor antagonists, palonosetron and netupitant, respectively.  He has an ongoing interest in broad inhibitory antiemetic drugs and works with several leading pharmaceutical companies to aid drug development.  He is serving concurrently as the Director of the Laboratory Animal Services Centre, The Chinese University of Hong Kong. 

  1. Characterizing the pharmacology of drugs to prevent chemotherapy-induced acute and delayed emesis using animal models with proven translational value; connection with the pharmaceutical industry to make discoveries a reality.
  2. Understanding mechanisms of gastric dysrhythmia following anticancer treatment; interstitial cells of Cajal (ICC); value of prokinetic drugs.
  3. Understanding mechanisms of cancer cachexia; development of meaningful animal models.
  4. Role of forebrain to brainstem mechanisms controlling feeding and homeostasis and behaviors indicative of nausea; emetic liability mechanisms. 
  5. Mechanisms of taste and smell alterations during chemotherapy.
  1. Lu, Z., Ngan, M. P., Lin, G., Yew, D. T. W., Fan, X., Andrews, P. L. R., & Rudd, J. A. (2017). Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39). Oncotarget, In Press.
  2. Tu, L., Lu, Z., Dieser, K., Schmitt, C., Chan, S. W., Ngan, M. P., Andrews, P. L. R., Nalivaiko, E., & Rudd J. A. (2017). Brain activation by H1 antihistamines challenges conventional view of their mechanism of action in motion sickness: a behavioral, c-fos and physiological study in Suncus murinus (House Musk Shrew). Frontier in Physiology, 8, 412.
  3. Lu, Z., Yeung, C. K., Lin G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2017). Insight into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret. Autonomic Neurosciences, 202, 122-135.
  4. Ullah, I., Subhan, F., Lu, Z., Chan, S. W., & Rudd, J. A. (2017). Action of Bacopa monnieri to antagonize cisplatin-induced emesis in Suncus murinus (house musk shrew). Journal of Pharmacological Sciences, 133, 232-239.
  5. Kan, K. K. W., Wai, M. K. Jones, R. L., & Rudd, J. A. (2017). Role of prostanoid EP3/1 receptors in mechanisms of emesis and defaecation in ferrets. European Journal of Pharmacolgoy, 803, 112-117.
  6. Tu, L., Poppi, L., Rudd, J. A., Cresswell, E. T., Smith, D. W., Brichta, A., & Nalivaiko, E. (2017). Alpha-9 nicotinic acetylcholine receptors mediate hypothermic responses elicited by provocative motion in mice. Physiology and Behaviour, 174, 114-119.
  7. Rudd, J. A., Ngan, M. P., Lu, Z., Higgins, G., Giuliano, C., Lovati, E., & Pietra, C. (2016). Profile of antiemetic activity of netupitant alone or in combination with palonosetron and dexamethasone in ferrets and Suncus murinus (house musk shrew). Frontiers in Pharmacology, 7, 263.
  8. Guimaraes, D. D., Andrews, P. L. R., Rudd, J. A., Braga, V. A., & Nalivaiko, E. (2016). Ondansetron and promethazine have differential effects on hypothermic responses to lithium chloride administration and to provocative motion in rats. Temperature, 2, 543-553.
  9. Rudd, J. A., Nalivaiko E., Matsuki, N., Wan C., & Andrews, P. L. R. (2015). The involvement of TRPV1 in emesis and anti-emesis. Temperature, 2, 258-276.
  10. Andrew, P. L. R., & Rudd, J. A. (2015). The physiology and pharmacology of nausea and vomiting induced by anti-cancer chemotheraphy in humans. In: Management of chemotherapy-induced nausea and vomiting: new agents and new uses of current agents, R. Navari, Editor. Springer Health Care Publishers: London, England.
  11. Sin, T.K., Tam, B.T., Yung, B.Y., Yip, S.P., Chan, L.W., Wong, C.S., Ying, M., Rudd, J. A., & Siu, P.M. (2015). Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. Journal of Physiology, 593, 1887-1899.
  12. Lu, Z., Percie du Sert, N., Chan, S. W., Yeung, C. K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2015). Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. Journal of Translational Medicine, 12, 1-13.
  13. Nalivaiko, E., Rudd, J. A., & So, R. (2014). Motion sickness, nausea and thermoregulation: the "toxic" hypothesis. Temperature, 1, 164-171.
  14. Ullah, I., Subhan, F., Rudd, J. A., Rauf, K., Alam, J., Shahid, M., & Sewll, R. D. E. (2014). Attenuation of cisplatin-induced emetogenesis by standardized Bacopa monnieri extracts in the pigeon: behavioral and neurochemical correlations. Planta Medica, 80, 1569-1579.
  15. Ngampramuan, S., Cerri, M., Vecchio, F. D., Corrigan, J. J., Kamphee, A., Dragic, A. S., Rudd, J. A., Romanovsky, A. A., & Nalivaiko, E. (2014). Thermoregulatory correlates of nausea in rats and musk shrews. Oncotarget, 5, 1565-1575.
  16. Johnston, K. D., Lu, Z., & Rudd, J. A. (2014). Looking beyond 5-HT3 receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting. European Journal of Pharmacology, 722, 13-25.
  17. Chan, S.W., Lu, Z., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2014). The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew). Neuropharmacology, 83, 71-78.
  18. Chan, S. W., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2013). Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew). Neuropharmacology, 70, 141-147.
  19. Chan, S. W., Lin, Ge., Yew, D. T. W., & Rudd, J. A. (2011). A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew). European Journal of Pharmacology, 668, 340-346.
  20. Law, J. K., Yeung, C. K., Wan, S. P., Ingebrandt, S., Lau, H. Y., Rudd, J. A., & Chan, M. (2011). The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochimica et Biophysica Acta, 1810, 867-874.
  21. Percie du Sert, N., Rudd, J. A., Apfel, C. C., & Andrews, P. L. R. (2011). Systematic review and meta-analysis of the efficacy of 5-HT3 receptor antagonists in the ferret model of cisplatin-induced emesis. Cancer Chemotherapy and Pharmacology, 67, 667-686.
  22. Percie du Sert, N., Ho, W. S. V., Rudd, J. A., & Andrews, P. L. R. (2010). Cannabinoid-induced reduction in antral pacemaker frequency: a telemetric study in the ferret. Neurogastroenterology and Motility, 22, 1257-e324.
  23. Percie du Sert, N., Chu, K. M., Wai, M. K., Rudd, J. A., & Andrews, P. L. R. (2010). Telemetry in a motion-sickness model implicates the abdominal vagus in motion-induced gastric dysrhythmia. Experimental Physiology, 95(7), 768-773.
  24. Chu, K. M., Ngan, M. P., Wai, M. K., Yeung, C. K., Andrews, P. L. R., Percie du Sert, N., Lin, G., & Rudd, J. A. (2010). Olvanil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret. Toxicology Letters, 192, 402-407.
  25. Chu, K. M., Yeung, C. K., Ngan, M. P., Wai, M. K., Andrews, P. L. R., Percie du Sert, N., & Rudd, J. A. (2010). Olvanil: a non-pungent TRPV1 activator has anti-emetic properties in the ferret. Neuropharmacology, 58, 383-391.
  26. Percie du Sert, N., Chu, K. M., Wai, M. K., Rudd, J. A., & Andrews, P. L. R. (2009). Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets. World Journal of Gastroenterology, 15, 6034-6043.
  27. Percie du Sert, N., Rudd, J. A., Moss, R., & Andrews, P. L. R. (2009). The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neuroscience Letters, 465, 16-20.
  28. Kan, K. K. W., Ngan, M. P., Wai, M. K., & Rudd, J. A. (2008). Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. Naunyn Schmiedeberg's Archieves of Pharmacology, 378, 655-661.
  29. Sam, T. S. W., Ngan, M. P., Riendeau, D., Robichaud, A., & Rudd, J. A. (2007). Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. Journal of Pharmacological Sciences, 103, 189-200.
  30. Yamamoto, K., Chan, S. W., Rudd, J. A., Lin G., Asano, K., & Yamatodani, A. (2009). Involvement of hypothalamic glutamate in cisplatin-induced emesis in Suncus murinus (hourse musk shrew). Journal of Pharmacological Sciences, 109, 631-634.
  1. RGC - General Research Fund [PI; 01-Jan-19]: "Action of Ghrelin to Prevent Chemotherapy-Induced Side Effects in Suncus murinus" (HK$864,742).
  2. XW Laboratories, Inc. [PI; 06-Sep-18]: "Investigation of a Novel Compound to Inhibit Emesis" (HK$532,109).
  3. Millennium Pharmaceuticals, Inc. [PI; 25-Apr-18 to 24-May-21]: "Anti-emetic Action of Drugs Acting at the Area Postrema to Inhibit Emesis" (HK$17,932,427).
  4. Helsinn Heathcare SA [PI; 09-Aug-17]: "Emesis Research Group" (HK$350,000).
  5. NeuroDetective International Inc. [PI; 22-Dec-14 to 21-Feb-15]: "Investigation of a Novel Compound to Anatgonize Motion-Induced Emesis in Suncus murinus (House Musk Shrew)" (HK$121,438).